Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13452)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 21, 2017 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i35/6385.htm |
| Number | Citing Articles |
| 1 |
Filip Romaniuk, Anna Franus, Aleksandra Sobolewska-Włodarczyk, Anita Gąsiorowska. Clinical Utility of Disease Activity Indices in Predicting Short-Term Response to Biologics in Patients with Ulcerative Colitis. Journal of Clinical Medicine 2024; 13(12): 3455 doi: 10.3390/jcm13123455
|
| 2 |
Xue-Liang Sun, Shi-Yi Chen, Shan-Shan Tao, Li-Chao Qiao, Hong-Jin Chen, Bo-Lin Yang. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World Journal of Gastroenterology 2020; 26(14): 1554-1563 doi: 10.3748/wjg.v26.i14.1554
|
| 3 |
Rebecca L. Smith, Kirstin M. Taylor, Antony B. Friedman, David J. Gibson, Danny Con, Peter R. Gibson. Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 2022; 34(6): 613 doi: 10.1097/MEG.0000000000002367
|
| 4 |
Zhe Han, Liying Shi. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochemical and Biophysical Research Communications 2018; 495(1): 947 doi: 10.1016/j.bbrc.2017.11.121
|
| 5 |
Hee-Sook Lim, Soon-Kyung Kim, Su-Jin Hong. Food Elimination Diet and Nutritional Deficiency in Patients with Inflammatory Bowel Disease. Clinical Nutrition Research 2018; 7(1): 48 doi: 10.7762/cnr.2018.7.1.48
|
| 6 |
Mohamed Attauabi, Johan Burisch, Ole Haagen Nielsen, Jakob Benedict Seidelin. In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis. Inflammatory Bowel Diseases 2024; 30(10): 1931 doi: 10.1093/ibd/izae183
|
| 7 |
Cathy McShane, Rachel Varley, Anne Fennessy, Clodagh Byron, John Richard Campion, Karl Hazel, Conor Costigan, Eabha Ring, Alan Marrinan, Ciaran Judge, Kathleen Sugrue, Garret Cullen, Cara Dunne, Karen Hartery, Marietta Iacucci, Orlaith Kelly, Jan Leyden, Susan McKiernan, Aoibhlinn O'Toole, Juliette Sheridan, Eoin Slattery, Karen Boland, Deirdre McNamara, Laurence Egan, Subrata Ghosh, Glen Doherty, Jane McCarthy, David Kevans. Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease. Digestive and Liver Disease 2024; doi: 10.1016/j.dld.2024.08.055
|
| 8 |
Gerard Grau, Ariadna Altadill, Eduard Brunet-Mas, Xavier Calvet. Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis. Gastroenterología y Hepatología 2024; 47(1): 72 doi: 10.1016/j.gastrohep.2023.01.005
|
| 9 |
Dario Sorrentino, Vu Q. Nguyen, Kim Love. Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease. Digestive Diseases 2021; 39(6): 626 doi: 10.1159/000515432
|
| 10 |
Zahra Ghafouri, Saeid Seyyedian, Jafar Nikbakht, Ebrahim Kouhsari, Sara Bayat, Hamidreza Zargar, Gholamreza Houshmand. Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice. The Korean Journal of Gastroenterology 2020; 75(1): 39 doi: 10.4166/kjg.2020.75.1.39
|
| 11 |
Julián Panés, Javier P. Gisbert. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019; 42(6): 403 doi: 10.1016/j.gastrohep.2019.03.002
|
| 12 |
James J. Ashton, R. Mark Beattie. Treatment of Active Crohn’s Disease With an Ordinary Food-Based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019; 157(4): 1160 doi: 10.1053/j.gastro.2019.01.277
|
| 13 |
Lieven Pouillon, Johan Van Stappen, Peter Bossuyt, Silvio Danese, Laurent Peyrin-Biroulet. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 2018; : 17 doi: 10.1016/j.bpg.2018.05.006
|
| 14 |
Saumy Dewi Ratih, Firdian Makrufardi, Annisa Fairuz Nur Azizah, Wahyu Damayanti. Multiple mesenteric lymphadenopathies in pediatric with ulcerative colitis: A case report. Radiology Case Reports 2024; 19(2): 600 doi: 10.1016/j.radcr.2023.10.046
|
| 15 |
Edward V. Loftus, Jean-Frederic Colombel, Ken Takeuchi, Xiang Gao, Remo Panaccione, Silvio Danese, Marla Dubinsky, Stefan Schreiber, Dapo Ilo, Tricia Finney-Hayward, Wen Zhou, Charles Phillips, Yuri Sanchez Gonzalez, Lei Shu, Xuan Yao, Qing Zhou, Séverine Vermeire. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. Clinical Gastroenterology and Hepatology 2023; 21(9): 2347 doi: 10.1016/j.cgh.2022.11.029
|
| 16 |
Sara Nieves Ramos-Cozar, Rafael Martín-Masot, Begoña Rodríguez-Gallego, Leticia Rubio, Juan Luis Cabanillas-Moruno, Víctor Manuel Navas-López. Evaluación de la duración de la baja laboral en pacientes con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2024; 47(9): 502194 doi: 10.1016/j.gastrohep.2024.502194
|
| 17 |
Neeraj Narula, Emily C.L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease. Clinical Gastroenterology and Hepatology 2022; 20(7): 1579 doi: 10.1016/j.cgh.2021.04.006
|
| 18 |
Jean-Frédéric Colombel, Bruce E. Sands, Christopher Gasink, Benjamin Yeager, Omoniyi J. Adedokun, James Izanec, Tony Ma, Long-Long Gao, Scott D. Lee, Stephan R. Targan, Subrata Ghosh, Stephen B. Hanauer, William J. Sandborn. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2024; 22(1): 144 doi: 10.1016/j.cgh.2023.06.014
|
| 19 |
Mick J.M. van Eijs, José J.M. ter Linde, Matthijs J.D. Baars, Mojtaba Amini, Miangela M. Laclé, Eelco C. Brand, Eveline M. Delemarre, Julia Drylewicz, Stefan Nierkens, Rik J. Verheijden, Bas Oldenburg, Yvonne Vercoulen, Karijn P.M. Suijkerbuijk, Femke van Wijk. Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis. iScience 2023; 26(10): 107891 doi: 10.1016/j.isci.2023.107891
|
| 20 |
Danny Con, Nina Parthasarathy, Maria Bishara, Raphael P Luber, Neetima Joshi, Anna Wan, James A Rickard, Tony Long, Declan J Connoley, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg, Abhinav Vasudevan. Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn’s Disease. Journal of Crohn's and Colitis 2021; 15(4): 583 doi: 10.1093/ecco-jcc/jjaa194
|
| 21 |
Neeraj Narula, Emily C.L. Wong, John K. Marshall, Vipul Jairath, Parambir S. Dulai, Walter Reinisch. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study. American Journal of Gastroenterology 2023; 118(1): 121 doi: 10.14309/ajg.0000000000001987
|
| 22 |
Guillaume Bonnaud, Yoram Bouhnik, Hervé Hagege, Xavier Hebuterne, Benjamin Pariente, Xavier Roblin, Laurent Peyrin-Biroulet. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Digestive and Liver Disease 2020; 52(7): 704 doi: 10.1016/j.dld.2020.03.033
|
| 23 |
Isadora Sayuri Macedo da Silva, Maria Paula Carlini Cambi, Daniéla Oliveira Magro, Paulo Gustavo Kotze. Perioperative Nutritional Optimization in Inflammatory Bowel Diseases: When and How?. Journal of Coloproctology 2021; 41(03): 295 doi: 10.1055/s-0041-1730369
|
| 24 |
Turki AlAmeel, Eman Al Sulais, Tim Raine. Methotrexate in inflammatory bowel disease. Saudi Journal of Gastroenterology 2022; 28(4): 250 doi: 10.4103/sjg.sjg_496_21
|
| 25 |
Evi Zhuleku, Daniel Wirth, Riikka Nissinen, Ivana Bravatà, Despina Ziavra, Andreas Duva, Jennifer Lee, Andreas Fuchs, Sabrina Mueller, Thomas Wilke, Bernd Bokemeyer. Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241262288
|
| 26 |
Julián Panés, Javier P. Gisbert. Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterología y Hepatología (English Edition) 2019; 42(6): 403 doi: 10.1016/j.gastre.2019.03.012
|
| 27 |
Shintaro Sagami, Taku Kobayashi, Kanako Aihara, Misaki Umeda, Kazuhiro Odajima, Hiromu Morikubo, Kunio Asonuma, Yusuke Miyatani, Tomohiro Fukuda, Mao Matsubayashi, Hiroki Kiyohara, Masaru Nakano, Toshifumi Hibi. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2022; 55(10): 1320 doi: 10.1111/apt.16817
|
| 28 |
Jurij Hanžel, Rocio Sedano, Jenny Jeyarajah, Guangyong Zou, Stefanie C McFarlane, Christopher Ma, Vipul Jairath. Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn’s Disease: Systematic Review and Meta-Regression. Inflammatory Bowel Diseases 2022; 28(9): 1462 doi: 10.1093/ibd/izac018
|
| 29 |
Andrew Dickerson, Jeannie S. Huang, Laura E. Bauman. Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Reports 2024; doi: 10.1002/jpr3.12124
|
| 30 |
Yan Xu, Aditi Sharma, Yang Chen, Honghui Zhou. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others. Current Pharmacology Reports 2019; 5(3): 115 doi: 10.1007/s40495-019-00180-x
|
| 31 |
Arthur Geraud, Paul Gougis, Aurore Vozy, Celine Anquetil, Yves Allenbach, Emanuela Romano, Elisa Funck-Brentano, Javid J. Moslehi, Douglas B. Johnson, Joe-Elie Salem. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology 2021; 61(1): 85 doi: 10.1146/annurev-pharmtox-022820-093805
|
| 32 |
Jean-Frédéric Colombel, Tadakazu Hisamatsu, Raja Atreya, Francesca Bresso, Lena Thin, Remo Panaccione, Rogério Serafim Parra, Sharanya Ford, Valencia P. Remple, Ana Paula Lacerda, Samuel I. Anyanwu, Madhuja Mallick, Andrew Garrison, Miguel Regueiro. Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Clinical Gastroenterology and Hepatology 2024; 22(8): 1668 doi: 10.1016/j.cgh.2024.02.027
|
| 33 |
Nikil Vootukuru, Abhinav Vasudevan. Approach to loss of response to advanced therapies in inflammatory bowel disease. World Journal of Gastroenterology 2024; 30(22): 2902-2919 doi: 10.3748/wjg.v30.i22.2902
|
| 34 |
Alessandro Armuzzi, Luisa Avedano, Kay Greveson, Taegyun Kang. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. Journal of Crohn's and Colitis 2019; 13(2): 259 doi: 10.1093/ecco-jcc/jjy150
|
| 35 |
Rafael Martín-Masot, Pilar Ortiz Pérez, Encarnación Torcuato Rubio, Javier Blasco Alonso, Marta Herrador López, Carmen Gallego Fernández, Víctor Manuel Navas-López. The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases. JPGN Reports 2021; 2(3): e100 doi: 10.1097/PG9.0000000000000100
|
| 36 |
Zuzana Reiss, Filip Rob, Martin Kolar, Dagmar Schierova, Jakub Kreisinger, Zuzana Jackova, Radka Roubalova, Stepan Coufal, Martin Mihula, Tomas Thon, Lukas Bajer, Michaela Novakova, Martin Vasatko, Klara Kostovcikova, Natalie Galanova, Milan Lukas, Miloslav Kverka, Jana Tresnak Hercogova, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. Frontiers in Cellular and Infection Microbiology 2023; 12 doi: 10.3389/fcimb.2022.1064537
|
| 37 |
Gerard Grau, Ariadna Altadill, Eduard Brunet-Mas, Xavier Calvet. Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis. Gastroenterología y Hepatología (English Edition) 2024; 47(1): 72 doi: 10.1016/j.gastre.2023.01.011
|
| 38 |
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Rakesh Kochhar, Rupa Banerjee, Saroj Kant Sinha, Siew Chien Ng, Stephen Hanauer, Suhang Verma, Usha Dutta, Vandana Midha, Varun Mehta, Vineet Ahuja, Ajit Sood. Use of thiopurines in inflammatory bowel disease: an update. Intestinal Research 2022; 20(1): 11 doi: 10.5217/ir.2020.00155
|
| 39 |
Samuel Sassine, Souhila Zekhnine, Marwa Qaddouri, Lisa Djani, Christine Cambron‐Asselin, Mathieu Savoie‐Robichaud, Yi Fan Lin, Kelly Grzywacz, Véronique Groleau, Martha Dirks, Éric Drouin, Ugur Halac, Valérie Marchand, Chloé Girard, Olivier Courbette, Natalie Patey, Dorothée Dal Soglio, Colette Deslandres, Prévost Jantchou. Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study. JGH Open 2021; 5(12): 1373 doi: 10.1002/jgh3.12684
|
| 40 |
Anne E. Levine, Dominique Mark, Laila Smith, Hengqi B. Zheng, David L. Suskind. Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases. Pharmaceutics 2023; 15(3): 969 doi: 10.3390/pharmaceutics15030969
|
| 41 |
Rotem Sigall Boneh, Johan Van Limbergen, Eytan Wine, Amit Assa, Ron Shaoul, Peri Milman, Shlomi Cohen, Michal Kori, Sarit Peleg, Avi On, Hussein Shamaly, Lee Abramas, Arie Levine. Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021; 19(4): 752 doi: 10.1016/j.cgh.2020.04.006
|
| 42 |
Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, María Esteve, Luisa Castro-Laria, Santiago García-López, Daniel Ceballos, Ana Echarri, María Dolores Martín-Arranz, David Busquets, Jordina Llaó, Mercè Navarro-Llavat, José María Huguet, Federico Argüelles-Arias, Raquel Vicente, José Miguel Boudet, Gema Díaz, Ana M. Sánchez-Migallón, Francesc Casellas. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. Gastroenterología y Hepatología 2022; 45(3): 165 doi: 10.1016/j.gastrohep.2021.04.010
|
| 43 |
Simon Wetzel, Alexander Müller, Eva Kohnert, Negin Mehrbarzin, Roman Huber, Georg Häcker, Clemens Kreutz, Ann-Kathrin Lederer, Mohamed Tarek Badr. Longitudinal dynamics of gut bacteriome and mycobiome interactions pre- and post-visceral surgery in Crohn’s disease. Frontiers in Cellular and Infection Microbiology 2024; 13 doi: 10.3389/fcimb.2023.1275405
|
| 44 |
Marco Vincenzo Lenti, Vivien Dolby, Tanya Clark, Veronica Hall, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Rachael Walker, Karen Kemp, Simon Borg‐Bartolo, Jimmy K. Limdi, Jo Taylor, Tristan Townsend, Sree Subramanian, Daniel Storey, Arash Assadsangabi, Catherine Stansfield, Paul Smith, Debra Byrne, Annalisa De Silvestri, Christian P. Selinger. A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II. Alimentary Pharmacology & Therapeutics 2022; 55(7): 856 doi: 10.1111/apt.16742
|
| 45 |
Ashish R Srinivasan. Treat to target in Crohn’s disease: A practical guide for clinicians. World Journal of Gastroenterology 2024; 30(1): 50-69 doi: 10.3748/wjg.v30.i1.50
Abstract(406) |
Core Tip(422) |
Full Article(HTML)(5026)
|
Full Article with Cover (PDF)-2334K(167)
|
Full Article (Word)-573K(29)
|
Audio-403K(13)
|
Peer-Review Report-232K(45)
|
Answering Reviewers-60K(49)
|
Full Article (PDF)-922K(524)
|
Full Article (XML)-347K(45)
|
Times Cited (6)
|
Total Visits (7881)
|
Open
|
| 46 |
Katherine C Dodd, Rohan Ahmed, Philip Ambrose, James KL Holt, Saiju Jacob, M Isabel Leite, James AL Miller, Pyae Phyo San, Jennifer Spillane, Stuart Viegas, Jon Sussman. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis. Neuromuscular Disorders 2024; 38: 51 doi: 10.1016/j.nmd.2024.03.010
|
| 47 |
Réme Mountifield. Anti‐tumor necrosis factors (TNFs) are outdated—It's time to move on: Session three summary. Journal of Gastroenterology and Hepatology 2021; 36(S1): 25 doi: 10.1111/jgh.15455
|
| 48 |
Rami Sabouni, Toulin Al-Atassi, Khaled Ibrahim, Badie Alkouri. Idiopathic AA amyloidosis presenting with gastrointestinal manifestations mimicking inflammatory bowel disease: A case report. Medical Reports 2024; 6: 100075 doi: 10.1016/j.hmedic.2024.100075
|
| 49 |
Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02559-5
|
| 50 |
Ping Zhu, Jin-fang Sun, Yun-fei Gu, Hong-jin Chen, Min-min Xu, You-ran Li, Bo-lin Yang. Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-021-02078-9
|
| 51 |
Sara Nieves Ramos-Cozar, Rafael Martín-Masot, Begoña Rodríguez-Gallego, Leticia Rubio, Juan Luis Cabanillas-Moruno, Víctor Manuel Navas-López. Assessment of the length of sick leave in patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2024; 47(9): 502194 doi: 10.1016/j.gastre.2024.502194
|
| 52 |
Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Review of Gastroenterology & Hepatology 2024; 18(8): 421 doi: 10.1080/17474124.2024.2397650
|
| 53 |
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta. Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?. Intestinal Research 2022; 20(3): 297 doi: 10.5217/ir.2021.00099
|
| 54 |
Johan F K F Ilvemark, Tawnya Hansen, Thomas M Goodsall, Jakob B Seidelin, Heba Al- Farhan, Mariangela Allocca, Jakob Begun, Robert V Bryant, Dan Carter, Britt Christensen, Marla C Dubinsky, Krisztina B Gecse, Torsten Kucharzik, Cathy Lu, Christian Maaser, Giovanni Maconi, Kim Nylund, Carolina Palmela, Stephanie R Wilson, Kerri Novak, Rune Wilkens. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. Journal of Crohn's and Colitis 2022; 16(4): 554 doi: 10.1093/ecco-jcc/jjab173
|
| 55 |
Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, María Esteve, Luisa Castro-Laria, Santiago García-López, Daniel Ceballos, Ana Echarri, María Dolores Martín-Arranz, David Busquets, Jordina Llaó, Mercè Navarro-Llavat, José María Huguet, Federico Argüelles-Arias, Raquel Vicente, José Miguel Boudet, Gema Díaz, Ana M. Sánchez-Migallón, Francesc Casellas. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. Gastroenterología y Hepatología (English Edition) 2022; 45(3): 165 doi: 10.1016/j.gastre.2021.04.007
|
| 56 |
Christopher Ma, Jeffrey K. Lee, Anish R. Mitra, Anouar Teriaky, Daksh Choudhary, Tran M. Nguyen, Niels Vande Casteele, Reena Khanna, Remo Panaccione, Brian G. Feagan, Vipul Jairath. Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2019; 50(1): 5 doi: 10.1111/apt.15297
|
| 57 |
Beth-Ann Norton, Anne Sullivan, Jennifer Senior, Ninfa Candela, Mary Jason, Katherine Weyant. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022; 18(4): 438 doi: 10.1016/j.nurpra.2021.12.001
|
| 58 |
Gregory Gaspard, Samir Hussaini, Dileep Mandali, Ethan Lieberamn. Clinical Approaches to Hospital Medicine. 2022; : 23 doi: 10.1007/978-3-030-95164-1_2
|
| 59 |
Matheus Ferreira de Carvalho, Alexandre de Sousa Carlos, Angelo So Taa Kum, Alexandre Moraes Bestetti, Igor Logetto Caetité Gomes, Luiza Bicudo de Oliveira, Luiza Martins Baroni, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura. Invasive Therapeutic Strategies for Stricturing Crohn’s Disease in Childhood: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2024; doi: 10.1093/ibd/izae144
|
| 60 |
Maia Kayal, Shailja Shah. Ulcerative Colitis: Current and Emerging Treatment Strategies. Journal of Clinical Medicine 2019; 9(1): 94 doi: 10.3390/jcm9010094
|
| 61 |
Andrea Cassinotti, Alberto Batticciotto, Marco Parravicini, Maurizio Lombardo, Paolo Radice, Claudio Camillo Cortelezzi, Simone Segato, Federico Zanzi, Antonella Cappelli, Sergio Segato. Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221085889
|